{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.03 vs. cons $1.99",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.94B vs. cons $1.93B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic orders growth / book-to-bill (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred book-to-bill ~1.03 (organic orders ~+8%) vs. cons ~1.00 (~+7%)",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guide (raise)",
      "prediction": "BETTER",
      "answer": "guide ~$8.05-$8.19 (mid ~$8.14) vs. cons $8.10 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 organic sales growth guide",
      "prediction": "BETTER",
      "answer": "guide ~6% organic vs. cons ~5% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Q3 2026 Adjusted EPS guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.00 vs. cons $2.02 (Q3 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Core incremental margins commentary",
      "prediction": "BETTER",
      "answer": "pred core incrementals ~45% vs. embedded guide ~35% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "M&A / capital deployment (large-deal optionality)",
      "prediction": "UNKNOWN",
      "answer": ">$5B deployable capacity vs. 0.7x net debt/EBITDA (current)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "Base case is another clean beat-and-raise, but the FY raise is essentially the Q2 beat flowing through (2H guide left conservative/implicitly unchanged), so out-quarter estimates barely rise. With the stock near 52-week highs on a premium multiple and a beat-raise fully priced, the initial pop lacks a strong upward-revision engine. Orders decelerating off the +23% Q1 record (tougher comps, harder EMG/medical 2H) risks a 'quality of print' debate. Absent a needle-moving M&A announcement, the day-1 gain tends to fade back toward flat over the week.",
  "day5_confidence": "LOW"
}